WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
Rhea-AI Summary
WuXi Biologics (2269.HK) has been named a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for the fifth consecutive year, ranking in the top 1% of pharmaceutical companies assessed. This recognition comes from Sustainalytics' evaluation of over 15,000 companies across 42 industries worldwide.
The company has achieved several notable ESG milestones, including:
- Inclusion in the UNGC 20 Case Examples of Sustainable Development
- MSCI AAA Rating and inclusion in Dow Jones Sustainability Indices
- EcoVadis Platinum Medal
- CDP Water Security 'A list' and 'A-' Climate Change score
- Selection as FTSE4Good Index Series Constituent
- Listing in Hang Seng ESG 50 Index
As a global Contract Research, Development and Manufacturing Organization (CRDMO), WuXi Biologics operates with over 12,000 employees across China, the United States, Ireland, Germany and Singapore, supporting 817 integrated client projects, including 21 in commercial manufacturing.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, WXXWY gained 2.21%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Ranked among the top
1% of companies assessed in the pharmaceutical industry - Recognized as a leader in Green CRDMO, driving innovation for a healthier future
- Committed to creating long-term value for all stakeholders
Sustainalytics, a leading ESG data, research, and ratings firm, supports global investors with the development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings cover more than 15,000 companies across 42 industries worldwide, with Top-Rated Badges given to those companies with the strongest ESG achievements. WuXi Biologics ranks in the top
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to once again receive this honor from Morningstar Sustainalytics. It is a reflection and recognition of our ongoing commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we consistently deliver our own ESG excellence while enabling partners worldwide to fulfill their ESG commitments, jointly working with all stakeholders to promote responsible practices throughout the entire value chain."
In recent years, WuXi Biologics' ESG strategy and initiatives have made significant progress and gained widespread recognition. The Company was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About Morningstar Sustainalytics
Morningstar Sustainalytics is a leading independent ESG and corporate governance research, ratings and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
FAQ
What ESG rating did WuXi Biologics (2269.HK) receive from Sustainalytics in 2025?
How many consecutive years has WuXi Biologics (2269.HK) maintained top ESG ratings?
How many integrated client projects is WuXi Biologics (2269.HK) supporting as of December 2024?
What major ESG recognitions has WuXi Biologics (2269.HK) received besides Sustainalytics?
How many employees does WuXi Biologics (2269.HK) have globally?
